Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentre, Open-label, Non-randomized, Phase 1b Trial of NG-350A, a Tumour-selective Anti-CD40-expressing Adenoviral Vector, in Combination With Chemoradiotherapy in Locally Advanced Rectal Cancer (FORTRESS)

NCT06459869 is registered in ClinicalTrials.gov with Akamis Bio as lead sponsor.

NCT NCT06459869
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06459869 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentre, Open-label, Non-randomized, Phase 1b Trial of NG-350A, a Tumour-selective Anti-CD40-expressing Adenoviral Vector, in Combination With Chemoradiotherapy in Locally Advanced Rectal Cancer (FORTRESS)
Lead sponsor
Akamis Bio
Phase
Phase 1
Overall status
Active, not recruiting
Start date
April 7, 2025
Completion date
December 30, 2028
Enrollment
30 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced rectal cancer (larc)